MedeliX
Start asking

Galantamine

Galantamin Actavis, Galantamin Krka, Galantamin Ratiopharm, Galantamin Sandoz · ATC code N06DA04

Also known as: Galantamin · Brand names: Galantamin Actavis, Galantamin Krka, Galantamin Ratiopharm, Galantamin Sandoz, Reminyl, Galanaxiro, Galnora, Masparen, Beklamen

Key facts
Active substance
Galantamine
Drug class
Antidementia agent
ATC code
N06DA04
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Galantamine is a cholinesterase inhibitor. Per the US prescribing information, the immediate-release tablets are used to treat mild to moderate dementia of the Alzheimer's type.

What it is used for

  • Mild to moderate dementia of the Alzheimer's type

Dosing

  • Start with 4 mg twice a day (8 mg/day), preferably with morning and evening meals
  • After at least 4 weeks increase to 8 mg twice a day (16 mg/day); after at least another 4 weeks a further increase to 12 mg twice a day (24 mg/day) should be attempted
  • Recommended range 16 to 24 mg/day; 32 mg/day is less well tolerated without added benefit
  • If treatment is interrupted for more than three days, restart at the lowest dose and titrate again; ensure adequate fluid intake
  • Moderate hepatic impairment or creatinine clearance 9 to 59 mL/min: generally not more than 16 mg/day; not recommended in severe hepatic impairment or creatinine clearance less than 9 mL/min

Contraindications

  • Known hypersensitivity to galantamine hydrobromide or any excipient

Important warnings

  • Serious skin reactions (Stevens-Johnson syndrome, acute generalized exanthematous pustulosis): stop at the first sign of rash unless clearly not drug-related
  • Bradycardia and all types of heart block; dose-related increase in syncope
  • Increased gastric acid secretion – monitor for gastrointestinal bleeding; weight should be monitored
  • Exaggerated effect of succinylcholine-type muscle relaxants during anesthesia
  • Possible bladder outflow obstruction, seizures; care in severe asthma or obstructive pulmonary disease
  • Deaths were reported in trials in mild cognitive impairment, for which it is not approved

Side effects

  • Most common (≥5%): nausea, vomiting, diarrhea, dizziness, headache and decreased appetite
  • Most common reasons for discontinuation: nausea (6.2%), vomiting (3.3%), decreased appetite (1.5%) and dizziness (1.3%)
  • Serious: bradycardia, heart block, syncope, serious skin reactions

Interactions

  • Anticholinergic medicines: galantamine may interfere with their activity
  • Succinylcholine, other cholinesterase inhibitors, similar neuromuscular blockers and cholinergic agonists such as bethanechol: synergistic effect

Pregnancy and breastfeeding

  • No adequate data in pregnant women; animal studies showed developmental toxicity at clinically relevant doses

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Austria

  • Galantamin ActavisActavis Group Ptc Ehf. · 1 register entry
  • Galantamin KrkaKrka, D.D., Novo Mesto · 1 register entry
  • Galantamin RatiopharmTeva B.V · 1 register entry
  • Galantamin SandozSandoz Gmbh · 1 register entry
  • ReminylEssential Pharma Limited, Janssen-Cilag Pharma Gmbh · 3 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • GalanaxiroMedical Valley Invest Ab · 1 register entry
  • Galantamin1 A Pharma Gmbh, Neuraxpharm Arzneimittel Gmbh, Pharmathen S.A., Ratiopharm Gmbh, Glenmark Arzneimittel Gmbh, Heumann Pharma Gmbh & Co. Generica Kg · 7 register entries
  • GalnoraTad Pharma Gmbh · 1 register entry
  • MasparenPharmathen S.A. · 1 register entry
  • ReminylKohlpharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • BeklamenNEUTEC İLAÇ SAN. TİC. A.Ş · 9 register entries
  • ReminylJOHNSON AND JOHNSON SIHHİ MAL. SAN. VE TİC. LTD. ŞTİ. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 22 more European countries
Belgium
Reminyl
Bulgaria
Галантамин Дс, Галсия Sr, Нивалин
Denmark
Galantamin Krka, Galantamin Stada, Reminyl
Finland
Galantamin Krka, Galantamin Orion, Galantamin Stada, Reminyl
France
Galantamine Lp Arrow Lab, Galantamine Lp Biogaran, Galantamine Lp Krka, Galantamine Lp Teva Sante, Galantamine Lp Zentiva Lab, Reminyl
Greece
Aneprosil, Galantamine Pharmathen, Galanyl, Memo, Memoton-Life, Micol, Reminyl
Iceland
Galantamin Stada
Ireland
Galsya Sr
Italy
Galnora, Reminyl
Latvia
Nivalin
Liechtenstein
Reminyl
Luxembourg
Reminyl
Malta
Galantamine Syri Pharma
Netherlands
Bergal Sr, Galantamine Hydrobromide Aurobindo, Galantamine Retard Viatris, Galantamine Sandoz, Masparen Retard
Norway
Galantamin Krka, Reminyl
Poland
Nivalin
Portugal
Galantamina Azevedos, Galantamina Bluelife, Galantamina Ciclum, Galantamina Generis, Galantamina Krka, Galantamina Mylan, Galantamina Sandoz, Galantamina Sr Sandoz, Galantamina Teva, Galantamina Tolife, Galantamina Zentiva, Reminyl
Romania
Galsya, Reminyl
Slovakia
Galantamin Viatris, Galsya Sr
Slovenia
Galabar Sr, Galema Sr, Galsya Sr, Spegal Sr, Vertusal Sr
Spain
Galantamina Aurovitas Spain, Galantamina Cinfa, Galantamina Combix, Galantamina Kern Pharma, Galantamina Normon, Galantamina Sandoz, Galantamina Stada, Galantamina Tevagen, Galantamina Viatris, Galnora, Reminyl
Sweden
Galantamin Actavis, Galantamin Krka, Galantamin Sandoz, Galantamin Stada, Galantamine Medical Valley, Reminyl

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Galantamine (Aurobindo Pharma Limited) – Prescribing Information, 2024-02-08. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC N06DA.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.